From Enrollment to Administration, Get Tools to Streamline Your Practice and Support Families
Fensolvi TotalSolutions® Resources Available to You
Prescribe through an in-network pharmacy or the TotalSolutions Hub for access to prior authorization support, in-home injection, and patient assistance—plus, copay support and live assistance are available 6 days a week. Get the full list of services and more on the Distribution & Ordering page.
Or get more information for your practice on how to order Fensolvi and more.
Resources
Patient Access & Support
Resources to help patients order Fensolvi, access financial assistance, and manage reimbursement.
Patient Enrollment Form
In-home Injection Program Form
Patient Assistance Program Form
Application form for patients seeking financial assistance for Fensolvi treatment.
Reimbursement Savings Form
Form to facilitate reimbursement and savings for eligible patients.
Fensolvi Brand Promise Brochure
Key benefits and value of the Fensolvi brand.
Fensolvi Direct to Specialty Pharmacy Brochure
How to order Fensolvi through specialty pharmacies.
Fensolvi Buy and Bill Brochure
Guide to purchasing and billing Fensolvi.
Fensolvi Integrated Specialty Pharmacy Brochure
Info on integrated specialty pharmacy services for Fensolvi.
Clinical Documentation & Office Tools
Resources to help patients order Fensolvi, access financial assistance, and manage reimbursement.
Letter of Medical Necessity
Template to assist in documenting the medical necessity for Fensolvi treatment.
Fensolvi Product Summary
An overview of Fensolvi’s features, including dosing information and administration benefits.
In-Network Specialty Pharmacy
Resources to help patients order Fensolvi, access financial assistance, and manage reimbursement.
CONTACT ACCREDO
- NPI: 1346208949
- 1620 Century Center Pkwy.
- Memphis, TN 38134
- Phone: 855-315-3590
- Fax: 888-302-1028
CONTACT CVS
- NPI: 1134100134
- 800 Biermann Ct.
- Mount Prospect, IL 60056
- Phone: 877-722-3444
- Fax: 800-323-2445
Buy and Bill Distribution Partners
Access our trusted network of specialty distributors, including their Fensolvi item numbers, to simplify your Buy and Bill process.
Specialty Distribution Partners
| Distributor | Fensolvi Item Number |
|---|---|
| Cardinal Health Specialty | 5828934 |
| CuraScript SD | 468789 |
| McKesson Blood & Plasma | 2684389 |
Hospital Distribution Partners
| Distributor | Fensolvi Item Number |
|---|---|
| ICS-Amerisource Bergen | 16020163-60 |
| Cardinal Health | 5858014 |
| Henry Schein | 325-0455 |
| McKesson Blood & Plasma | 2684389 |
| Morris & Dickson | 555 |
Administration & Dosing Guides
Step-by-step resources for HCPs administering the product.
Mixing & Administration Guide
Step-by-step instructions for preparing and administering Fensolvi.
For Fensolvi Families: Answers, Access, and Assurance—all in one place
Clear, supportive brochures and videos for patients and caregivers.
What to expect
Learn how Fensolvi works, what to expect during treatment, and common caregiver questions.
What’s Happening
Get the full explanation of CPP and its impact, written for parents and caregivers.
Treatment Journal
Printable journal to help families track symptoms, milestones, and treatment progress.
Understanding CPP: A Clinical Insight
Angie, a pediatric pharmacist and mother, shares her daughter’s journey with CPP—from early signs and diagnosis challenges to choosing the right treatment with a coordinated care team. Learn how she navigated therapy selection.
Hear more from Angie
Recognizing and Diagnosing Central Precocious Puberty (CPP): Signs and Symptoms
Early Intervention in Central Precocious Puberty (CPP): Initial Treatment Approaches
Fensolvi: What Parents and Patients Can Expect From Treatment
Contact a Representative
Get in touch with a Tolmar representative for assistance.
CUSTOMER SERVICE
- Phone: 1-888-FENSOLVI (336-7658)
- Fax: 847-235-2933
- Email: fensolvi@tolmar.com
- Connect with Customer Service
ADVERSE EVENTS & PRODUCT COMPLAINTS
- Phone: 1-844-4TOLMAR (486-5627)
- Fax: 970-999-3907
- Email: tolmarproductsupport@tolmar.com
- Contact Adverse Events & Product Complaints
Connect with Fensolvi
Connect with a Fensolvi Representative
By providing your information, you are giving Tolmar, Inc. and other parties working with us permission to communicate with you about Fensolvi or other products, services, and offers from Tolmar, Inc. If you don’t find the information useful, you can opt out at any time. We value your privacy and we encourage you to review our privacy policy for more information.
"*" indicates required fields
Fensolvi Starter Kits
We’re excited to offer Fensolvi starter kits for new patients who have been prescribed Fensolvi. Each kit offers helpful information for caregivers plus engaging activities for children to enjoy during their visits. Contents include a treatment brochure, coloring and iSpy sheets, coloring pencils, a book of jokes, and coping cards—all inside a handy drawstring bag. Order kits for your patients by calling your Tolmar representative or completing the form.
Contact us at 1-866-FENSOLVI (336-7658)
"*" indicates required fields
Contact us to schedule a mixing and administration demonstration
We will only use your submission to communicate with you about scheduling a mixing and administration training and to share associated materials. Please see our privacy policy for more information.
Contact us at 1-866-FENSOLVI (336-7658)
"*" indicates required fields
Sign up to receive clinical and support updates
Complete the form below to receive emails featuring key updates related to Fensolvi. By providing your information, you are giving Tolmar, Inc. and other parties working with us permission to communicate with you about Fensolvi® or other products, services, and offers from Tolmar, Inc. If you don’t find the information useful, you can opt out at any time. We value your privacy and we encourage you to review our privacy policy for more information.
Contact us at 1-866-FENSOLVI (336-7658)
"*" indicates required fields
IMPORTANT SAFETY INFORMATION
FENSOLVI® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist used to treat patients 2 years of age and older with central precocious puberty (CPP). CPP may be diagnosed when signs of sexual maturity begin to develop in girls under the age of 8 or in boys under the age of 9.
FENSOLVI is contraindicated in individuals with hypersensitivity to any drug that is in the same class as FENSOLVI, in individuals who are allergic to any of the ingredients in FENSOLVI, or in individuals who are pregnant. FENSOLVI may cause fetal harm when administered to a pregnant patient.
During the first few weeks of treatment, increases in gonadotropins and sex steroids above baseline may result in an increase in signs and symptoms of puberty including vaginal bleeding in girls.
Psychiatric events have been reported in patients taking GnRH agonists. Events include emotional lability, such as crying, irritability, impatience, anger, and aggression. Patients should be monitored for development or worsening of psychiatric symptoms.
Convulsions have been observed in patients treated with GnRH agonists with or without a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs.
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis, have occurred in patients receiving GnRH agonists. Monitor for and advise patients of the signs and symptoms of SCARs.
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) has been reported in pediatric patients treated with GnRH agonists. Patients should be monitored for headache, papilledema and blurred vision.
The most common adverse reactions seen with FENSOLVI were: injection site pain, nasopharyngitis, pyrexia, headache, cough, abdominal pain, injection site erythema, nausea, constipation, vomiting, upper respiratory tract infection, bronchospasm, productive cough and hot flush.
Please see Full Prescribing Information for FENSOLVI for additional important safety information.
To report suspected adverse reactions contact Tolmar at 1-844-4TOLMAR (486-5627) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
IMPORTANT SAFETY INFORMATION
FENSOLVI® (leuprolide acetate) for injectable suspension is a gonadotropin releasing hormone (GnRH) agonist used to treat patients 2 years of age and older with central precocious puberty (CPP). CPP may be diagnosed when signs of sexual maturity begin to develop in girls under the age of 8 or in boys under the age of 9.
FENSOLVI is contraindicated in individuals with hypersensitivity to any drug that is in the same class as FENSOLVI, in individuals who are allergic to any of the ingredients in FENSOLVI, or in individuals who are pregnant. FENSOLVI may cause fetal harm when administered to a pregnant patient.
During the first few weeks of treatment, increases in gonadotropins and sex steroids above baseline may result in an increase in signs and symptoms of puberty including vaginal bleeding in girls.
Psychiatric events have been reported in patients taking GnRH agonists. Events include emotional lability, such as crying, irritability, impatience, anger, and aggression. Patients should be monitored for development or worsening of psychiatric symptoms.
Convulsions have been observed in patients treated with GnRH agonists with or without a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs.
Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis, have occurred in patients receiving GnRH agonists. Monitor for and advise patients of the signs and symptoms of SCARs.
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension) has been reported in pediatric patients treated with GnRH agonists. Patients should be monitored for headache, papilledema and blurred vision.
The most common adverse reactions seen with FENSOLVI were: injection site pain, nasopharyngitis, pyrexia, headache, cough, abdominal pain, injection site erythema, nausea, constipation, vomiting, upper respiratory tract infection, bronchospasm, productive cough and hot flush.
Please see Full Prescribing Information for FENSOLVI for additional important safety information.
To report suspected adverse reactions contact Tolmar at 1-844-4TOLMAR (486-5627) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
FENSOLVI TOTALSOLUTIONS COPAY PROGRAM TERMS AND CONDITIONS
The Fensolvi® Copay Assistance Program (“Program”) is valid ONLY for patients who are prescribed Fensolvi® and are reimbursed exclusively by commercial insurance. This Program is valid only in the United States; but, void where prohibited by law or by the patient’s health insurance provider. This Program is non-transferable, limited to one per person, and cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer. Restrictions or limits may apply.
Medicare, Medicaid, Tricare and other federal health care program beneficiaries may not participate in this Program. This Program also is neither available for cash paying patients nor where your commercial plan reimburses you for the entire cost of your prescription drug. Patients cannot seek reimbursement from health insurance or any third party for any part of the assistance received through this Program. The patient or his/her guardian is responsible for reporting the receipt of all benefits or reimbursement received under the Program to any insurer, health plan, or other third party, as may be required. This Program is not insurance and is not intended as a substitute for insurance.
With the Program, you pay as little as $5 of your co-pay or co-insurance for Fensolvi®, per prescription. The remainder of your co-pay or co-insurance is covered, up to two prescriptions per calendar year. The Program assists with the cost of Fensolvi only. It does not assist with the cost of other administrations, medicines, procedures or office visit fees.
Tolmar, Inc. (“Tolmar”) reserves the right to terminate, rescind, revoke, or modify this Program at any time without notice. This Program expires at the end of the current calendar year, at which time you must re-enroll. For complete information about the terms and conditions of this Program, including the limitations on use and the amount of assistance call 1 866-FENSOLVI (336-7658).
Program managed by Scripts Rx on behalf of Tolmar.
